Table 1:

Results of antimicrobial susceptibility tests of two bla_NDM-1 isolates described in this report

Antimicrobial agent	Isolate
	blaNDM-1-positive Morganella morganii*		blaNDM-1-positive Providencia rettgeri
	MIC, mg/L†	Interpretation§	MIC, mg/L†	Interpretation§
Ertapenem	4	R	8	R
Imipenem	16	R	≥ 32	R
Meropenem	8	R	≥ 32	R
Doripenem	≥ 8	R	≥ 8	R
Ampicillin	≥ 32‡	R	≥ 32‡	R
Amoxicillin/clavulinic acid	≥ 32/16‡	R	≥ 32/16‡	R
Cefazolin	≥ 64‡	R	≥ 64‡	R
Ceftriaxone	≥ 64‡	R	32‡	R
Ceftazidime	≥ 64	R	≥ 64	R
Cefepime	≥ 64	R	32	R
Amikacin	≥ 128	R	≥ 128	R
Gentamicin	≥ 32	R	≥ 32	R
Tobramycin	≥ 32	R	≥ 32	R
Ciprofloxacin	≥ 8	R	≥ 8	R
Nitrofurantoin	128‡	R	256‡	R
Tetracycline	≥ 32	R	≥ 32	R
Chloramphenicol	32	R	8	S
Colistin	≥ 16	R¶	≥ 16	R¶
Tigecycline	2	S**	1	S**

Note: MIC = minimum inhibitory concentration, NDM-1 = New Delhi metallo-β-lactamase-1, R = resistant, S= susceptible,

^*These results are from the second isolate of bla_NDM-1-positive Morganella morganii described in case one.

^†MICs are based on from frozen broth microdilution panels following the standards of the Clinical Laboratory Standards Institute,¹⁴ unless otherwise indicated.

^‡MICs are based on the Vitek-2 automated susceptibility testing system (bioMérieux, France).

^§Interpretations, when available, are provided from the Clinical Laboratory Standards Institute document no. M100-S21 (January 2011),¹⁰ unless otherwise indicated.

^¶Interpretation is provided based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints.¹⁵

^**Interpretation is provided based on the product monograph of Tygacil (tigecycline), approved by Health Canada.¹⁶